About Kyttaro Therapeutics
Kyttaro Therapeutics is a Healthcare company based in New York (United States) founded in 2021. It develops genetically modified stem cells for disease treatments with high unmet needs. It operates on a B2B model. Its website kyttarotherapeutics.com draws about 681 thousand monthly visits. Kyttaro Therapeutics offers products and services including MSC-AAT, MSC-Cyt, and MSC-Klotho. Its focus areas include Biotechnology, Stem Cell Research, Genetically Modified MSCs and Therapeutics. Its legal entity is Kyttaro Therapeutics, Inc. Similar companies include RoosterBio, Cellular Biomedicine Group and Osiris; 2 of its 3 listed similar companies have raised funding.
Company details
Kyttaro Therapeutics is a platform technology company specializing in genetically modified mesenchymal stem cells for clinical applications. It holds patents for treatments like MSC-AAT, MSC-Cyt, and MSC-Klotho, targeting diseases such as Graft Vs. Host Disease and Type 1 Diabetes. Based on 15 years of research in Germany and worldwide, the company focuses on preclinical evaluations and upcoming clinical trials in Europe and the US. It partners with investors to advance therapies for patients with high unmet medical needs.
- Headquarters New York, United States
- SectorsHealthcare
- Email••••••••
- Website kyttarotherapeutics.com
- Social LinkedIn X
- Legal Name Kyttaro Therapeutics, Inc.
Products & Services of Kyttaro Therapeutics
Kyttaro Therapeutics offers a comprehensive portfolio of products and services, including MSC-AAT, MSC-Cyt, and MSC-Klotho.
Treats diseases using genetically modified stem cells for alpha-1 antitrypsin.
Develops cytokine-based stem cell therapies for various medical conditions.
Focuses on stem cell modifications for treating kidney and related diseases.
Similar companies to Kyttaro Therapeutics
Kyttaro Therapeutics has 3 listed similar companies in our database, 2 of them funded. They include RoosterBio, Cellular Biomedicine Group and Osiris.
| Company Name | Domain | Founded | HQ Location | Total funding | Employees | Description |
|---|---|---|---|---|---|---|
| roosterbio.com | 2012 | Frederick, United States | $38.41M | 69 | Developer of human mesenchymal stem cells and extracellular vesicles | |
| cellbiomedgroup.com | 2001 | Cupertino, United States | $120M | Cellular therapeutics are developed for cancer, orthopaedics, and COPD. | ||
| osiris.com | 1992 | Baltimore, United States | 356 | Stem cell-based regenerative medicines are developed and marketed. |
Detailed similar companies of Kyttaro Therapeutics
The full competitor set, operating metrics and side-by-side benchmarks require an active premium plan.
- Full competitor set
- Operating metrics
- Benchmarks
- Competitive positioning
Verified entity values are shown only after access is granted.
Web traffic of Kyttaro Therapeutics
The website of Kyttaro Therapeutics (kyttarotherapeutics.com) receives about 680.7K visits a month.
- Monthly visits680.7K
▼ 6.7% vs previous month
Websites whose visitors overlap most with Kyttaro Therapeutics. Affinity shows how closely the audiences match.
| Website | Domain | Audience affinity | Monthly visits | Global rank | Profile |
|---|---|---|---|---|---|
| falconebiz.com | 100% | 959.8K | #63,970 | View details | |
| tofler.in | 97% | 556K | #105,509 | View details | |
| zaubacorp.com | 96% | 4.9M | #12,689 | View details | |
| tracxn.com | 92% | 2.9M | #16,597 | View details | |
| indiafilings.com | 90% | 2.1M | #29,959 | View details | |
| •••••••••• | ••••••.com | ••% | •.•M | #••••• | – |
| •••••••••• | ••••••.com | ••% | •.•M | #••••• | – |
| •••••••••• | ••••••.com | ••% | •.•M | #••••• | – |
All 40 similar websites and full traffic analytics for Kyttaro Therapeutics
The complete similar-websites list, audience overlap and engagement analytics require an active premium plan.
- 40 similar websites
- Audience overlap
- Engagement analytics
- Traffic by brand
Verified entity values are shown only after access is granted.
Top companies in Cell Therapy
3 companies that operate in the same segment as Kyttaro Therapeutics (Cell Therapy) in United States, ranked by their profile score on The Company Check.
| Company | Description | Founded | Location | Total funding | Revenue | Employees |
|---|---|---|---|---|---|---|
CAR T-cell and T-cell receptor immunotherapies for cancer are developed. | 2013 | Seattle, Washington, United States | USD 316.67 M | 520 | ||
CAR-T and TIL immunotherapies for solid tumors are developed. | 2018 | San Francisco, California, United States | USD 493 M | USD 36 K | 233 | |
Smart surgical devices for spinal surgery are developed. | 1997 | San Diego, California, United States | USD 54.1 M |
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Frequently Asked Questions about Kyttaro Therapeutics
Kyttaro Therapeutics was founded in 2021.
Kyttaro Therapeutics is headquartered in New York, United States. It is registered at New York, New York, United States.
Kyttaro Therapeutics is a platform technology company specializing in genetically modified mesenchymal stem cells for clinical applications. It holds patents for treatments like MSC-AAT, MSC-Cyt, and MSC-Klotho, targeting diseases such as Graft Vs. Host Disease and Type 1 Diabetes. Based on 15 years of research in Germany and worldwide, the company focuses on preclinical evaluations and upcoming clinical trials in Europe and the US. It partners with investors to advance therapies for patients with high unmet medical needs.
Kyttaro Therapeutics's top competitors include RoosterBio, Osiris and Cellular Biomedicine Group.
Kyttaro Therapeutics offers MSC-AAT, MSC-Cyt, and MSC-Klotho.
Kyttaro Therapeutics operates through Kyttaro Therapeutics, Inc..
The website of Kyttaro Therapeutics receives about 681 thousand visits a month.